Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.

Then David, who leads the Factor XI clinical program at Regeneron, will present preclinical data as well as clinical data from the ROXI-VTE-I and II studies in venous thromboembolism prevention post ...

Merck’s pill, which could be the first oral PCSK9 drug to get to market, displayed similar effects on lipid levels as ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

In a significant move reflecting confidence in the biopharmaceutical sector, Mitsubishi UFJ Asset Management Co. Ltd. has enhanced its investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.

Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary and secondary endpoints in a Phase III study in allergic fungal rhinosinusitis ...

An oral agent is needed because some patients don’t like injectables, and some doctors don’t prescribe them, experts say.

One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend ...

The LDL-C reductions seen with enlicitide in both studies are in the same ballpark as those seen with injectable ...

The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.

Clients and even lawyers from other firms have told me that they can tell our teams really enjoy working together. We believe ...